Last reviewed · How we verify
NCT02104986
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
Phase 2 trial testing Velbe-Bleomycin-Cisplatin in Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in 117 participants. Completed in 14 October 2021.
14 October 2021
Quick facts
| Lead sponsor | Centre Leon Berard |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 117 |
| Start date | 12 May 2014 |
| Primary completion | 14 October 2021 |
| Estimated completion | 14 October 2021 |
| Sites | 27 locations across France |
Drugs / interventions tested
- Velbe-Bleomycin-Cisplatin — full drug profile →
- Vepeside-ifosfamide-Cisplatin — full drug profile →
Conditions studied
- Extra Cranial Non Seminomateous Malignant Germ Cell Tumour — all drugs for Extra Cranial Non Seminomateous Malignant Germ Cell Tumour →
Sponsor
Centre Leon Berard — full company profile →
Who can join
Under 18, any sex, with Extra Cranial Non Seminomateous Malignant Germ Cell Tumour. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J, Vacchelli E, Aranda F, Castoldi F, et al · · 2015 · cited 238× · PMID 26137404 · DOI 10.1080/2162402x.2015.1008866
Verify or expand the search:
- PubMed search for NCT02104986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Leon Berard trials
Trials by the same sponsor.
- NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
- NCT07515274 — Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer · NA · not yet recruiting
- NCT07243483 — Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My · NA · recruiting
- NCT07334990 — Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Canc · NA · not yet recruiting
- NCT07414719 — Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02104986 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Leon Berard
- Last refreshed: 29 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02104986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing